Hikma's Sodium Butabarbital ANDA085432 Receives AP Status from FDA
Hikma's Abbreviated New Drug Application (ANDA085432) for Sodium Butabarbital has received an Approved Product (AP) status from the FDA.
Therapeutic Area
Therapeutic area intelligence for Sedative with 9 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.